Research graph
References from Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone‐sensitive prostate cancer: the <scp>ARASENS</scp> and <scp>LATITUDE trials</scp>. Local targets link to admitted publications; unresolved targets remain external evidence.
Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
1972 · External reference
Abiraterone plus prednisone in metastatic, castration‐sensitive prostate cancer
10.1056/nejmoa1704174 · 2017 · External reference
Abiraterone acetate plus prednisone in patients with newly diagnosed high‐risk metastatic castration‐sensitive prostate cancer (LATITUDE): final overall survival analysis
10.1016/s1470-2045(19)30082-8 · 2019 · External reference
ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone‐sensitive prostate cancer
10.1200/jco.19.00799 · 2019 · External reference
Apalutamide in patients with metastatic castration‐sensitive prostate cancer: final survival analysis of the randomized, double‐blind, phase III TITAN study
10.1200/jco.20.03488 · 2021 · External reference
Darolutamide and survival in metastatic, hormone‐sensitive prostate cancer
10.1056/nejmoa2119115 · 2022 · External reference
Unresolved reference
External reference
Expert perspectives on controversies in castration‐sensitive prostate cancer management: narrative review and report of the first US prostate cancer conference, part 1
10.1097/ju9.0000000000000137 · 2024 · External reference
Nadir testosterone within first year of androgen‐deprivation therapy predicts for time to castration‐resistant progression: a secondary analysis of the PR‐7 trial
10.1200/jco.2014.58.2973 · 2015 · External reference
Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy
10.1111/j.1464-410x.2008.08062.x · 2009 · External reference
Testosterone breakthrough rates during androgen deprivation therapy for castration‐sensitive prostate cancer
10.1097/ju.0000000000000809 · 2020 · External reference
Interpreting testosterone and concomitant prostate‐specific antigen values during androgen deprivation therapy for recurrent prostate cancer
10.1097/ju.0000000000001946 · 2021 · External reference
Lower testosterone level and metastases‐free survival in patients with nonmetastatic castration‐resistant prostate cancer treated with novel antiandrogens: a post hoc analysis of SPARTAN and ARAMIS
10.1097/ju.0000000000004545 · 2025 · External reference
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies
10.7326/0003-4819-147-8-200710160-00010 · 2007 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
